Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Head and Neck Neoplasms 2Carcinoma, Renal Cell 2Bites and Stings 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Oligoprogressive 1Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 1Nivolumab 1Immune Checkpoint Inhibitors 1DEAE-Dextran 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Oligoprogressive × Immune Checkpoint Inhibitors × Clear all
NCT05846659 2026-05-15

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated
16 enrolled 13 charts

Oligoprogressive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡